Online inquiry

IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13138MR)

This product GTTS-WQ13138MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets APP gene. The antibody can be applied in Alzheimer's disease (AD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_000484.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 351
UniProt ID P05067
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-APP, PF-04360365(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ13138MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12229MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ13870MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN-1979
GTTS-WQ1126MR IVTScrip™ mRNA-Anti-CD40, ABBV-927(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ABBV-927
GTTS-WQ15482MR IVTScrip™ mRNA-Anti-MAPT, UCB-0107(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA UCB-0107
GTTS-WQ3309MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ11791MR IVTScrip™ mRNA-Anti-IL23A, MK-3222(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-3222
GTTS-WQ6563MR IVTScrip™ mRNA-Anti-EGFR, DC-1630423(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA DC-1630423
GTTS-WQ9280MR IVTScrip™ mRNA-Anti-TACSTD2, IMMU-132(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMMU-132
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW